Belatacept-based immunosuppression: A calcineurin inhibitor-sparing regimen in heart transplant recipients. Belatacept (BTC) is indicated for prophylaxis of graft rejection in adults receiving a renal transplant (Tx). This retrospective observational study (three centers) included all heart transplant recipients receiving BTC between January 2014 and October 2018. Forty EBV+ patients mean GFR 35 ± 20 mL/min/m 'clinical research/practice', 'heart transplantation/cardiology', 'immunosuppressant - fusion proteins and monoclonal antibodies: belatacept', 'kidney failure / injury'